Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:REXN

Rexahn Pharmaceuticals (REXN) Stock Price, News & Analysis

Rexahn Pharmaceuticals logo

About Rexahn Pharmaceuticals Stock (NASDAQ:REXN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.81
$2.24
52-Week Range
N/A
Volume
2,579 shs
Average Volume
162,968 shs
Market Capitalization
$8.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive REXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rexahn Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REXN Stock News Headlines

Aurinia Pharmaceuticals Inc AUPH
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
Rexahn: Holes Galore in Serdaxin Data
See More Headlines

REXN Stock Analysis - Frequently Asked Questions

Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) posted its earnings results on Wednesday, August, 7th. The company reported ($0.61) earnings per share for the quarter, topping analysts' consensus estimates of ($0.95) by $0.34.

Rexahn Pharmaceuticals's stock reverse split before market open on Friday, April 12th 2019.The 1-12 reverse split was announced on Wednesday, April 10th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 11th 2019. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rexahn Pharmaceuticals investors own include TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), CorMedix (CRMD), SELLAS Life Sciences Group (SLS), Dynavax Technologies (DVAX), Imunon (CLSN) and AcelRx Pharmaceuticals (ACRX).

Company Calendar

Last Earnings
8/07/2019
Today
7/12/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:REXN
CIK
1228627
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.64 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-72.60%
Return on Assets
-55.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.37
Quick Ratio
3.37

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.48 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
4,483,000
Free Float
N/A
Market Cap
$8.11 million
Optionable
Optionable
Beta
0.98
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:REXN) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners